AtriCure Inc reported strong second-quarter results with worldwide revenue of $154 million, representing 13% year-over-year growth. US revenue reached $125.6 million, up 13.6%, whilst international revenue grew 9.6% to $28 million. The medical device company achieved significant profitability improvements, posting net income of $9 million compared to a net loss of $6.2 million in the prior year. Adjusted EBITDA exceeded $27 million, with gross margin expanding to 77.2%. Pain management revenue led growth at 27.8% to $27.1 million, driven by adoption of cryoSPHERE MAX. Appendage management revenue increased 14.4% to $51.6 million, whilst open ablation revenue rose 12.1% to $40.9 million. The company raised full-year revenue guidance to $602-610 million, reflecting 12.5-14% growth over 2025. Adjusted EBITDA guidance was increased to $85-89 million. AtriCure also reported its BoxX-NoAF clinical study surpassed 50% enrollment ahead of schedule.

AtriCure, a medical device company focused on atrial fibrillation treatments, reported first-quarter 2026 revenue of $141.2 million, up 14.3% year over year and exceeding analyst estimates by 1.4%. Growth was driven by a 28% increase in the pain management segment, led by its cryoSPHERE MAX probe. The company announced it has accelerated its BoxX-NoAF clinical trial timeline by 12 months, with patient enrollment now expected to complete by year-end and results potentially available in 2027 instead of 2028. The trial tests a minimally invasive procedure for treating atrial fibrillation. Following the results, Needham reiterated its Buy rating with a $45 price target on 6 May, citing the accelerated trial timeline as a major development that could unlock significant new market opportunities.

AtriCure expects 12% to 14% revenue growth in 2026, driven by recent and upcoming product launches including cryoSPHERE MAX, cryoXT and new appendage-management devices. President and CEO Michael Carrel and CFO Angela Wirick discussed the outlook at a Bank of America fireside chat, following 15% revenue growth in 2025. The company's EnCompass ablation platform and AtriClip continue to show significant runway, with executives citing a large untapped cardiac-surgery market and strong surgeon adoption. A next-generation V-Clip appendage product is expected in 2027. AtriCure guided 2026 adjusted EBITDA at $80 million to $82 million whilst maintaining profitability improvements. The cryoXT device, targeting lower-extremity amputations, had a soft launch in late 2025 and is expected to contribute more meaningfully in the second half of 2026.